{"url_path":"/sec/dwtx/8-k/2026-05-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1818844/0001104659-26-060747-index.html","accession_number":"0001104659-26-060747","cik":"0001818844","ticker":"DWTX","issuer_name":"Dogwood Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1818844/0001104659-26-060747-index.html","primary_entity_key":"0001818844","primary_entity_name":"Dogwood Therapeutics, Inc."},"word_count":114,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n​\n\n(d)Exhibits.\n\n​\n\n​\n\n​\n\n​\n\n**Exhibit Number**\n\n  ​ ​ ​\n\n**Description**\n\n99.1\n\n​\n\n[Press Release of the Company, dated May 14, 2026 (furnished herewith).](dwtx-20260514xex99d1.htm)\n\n104\n\n​\n\nCover Page Interactive Data File (formatted in Inline XBRL)\n\n​\n\n​\n\n​\n\n2\n\n**SIGNATURES**\n\n​\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n​\n\n​\n\n​\n\n​\n\n \n\n**DOGWOOD THERAPEUTICS, INC.**\n\n \n\n \n\n \n\n \n\nBy:\n\n/s/ Angela Walsh\n\n \n\nName:\n\nAngela Walsh\n\n​\n\nTitle:\n\nChief Financial Officer, Corporate Secretary and Treasurer\n\nMay 14, 2026\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n3"}